![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: VARS2 |
Gene summary for VARS2 |
![]() |
Gene information | Species | Human | Gene symbol | VARS2 | Gene ID | 57176 |
Gene name | valyl-tRNA synthetase 2, mitochondrial | |
Gene Alias | COXPD20 | |
Cytomap | 6p21.33 | |
Gene Type | protein-coding | GO ID | GO:0006082 | UniProtAcc | B4E0K6 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
57176 | VARS2 | HCC1_Meng | Human | Liver | HCC | 4.82e-28 | 4.47e-02 | 0.0246 |
57176 | VARS2 | HCC1 | Human | Liver | HCC | 3.47e-03 | 2.54e+00 | 0.5336 |
57176 | VARS2 | HCC2 | Human | Liver | HCC | 4.29e-13 | 3.64e+00 | 0.5341 |
57176 | VARS2 | S028 | Human | Liver | HCC | 6.34e-05 | 2.80e-01 | 0.2503 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00346601 | Liver | HCC | ncRNA metabolic process | 332/7958 | 485/18723 | 1.48e-31 | 7.80e-29 | 332 |
GO:00065202 | Liver | HCC | cellular amino acid metabolic process | 167/7958 | 284/18723 | 1.91e-08 | 4.56e-07 | 167 |
GO:0006399 | Liver | HCC | tRNA metabolic process | 108/7958 | 179/18723 | 1.07e-06 | 1.59e-05 | 108 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
VARS2 | SNV | Missense_Mutation | novel | c.1040N>C | p.Leu347Pro | p.L347P | Q5ST30 | protein_coding | deleterious(0) | probably_damaging(0.977) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
VARS2 | SNV | Missense_Mutation | rs748662260 | c.974N>A | p.Arg325Gln | p.R325Q | Q5ST30 | protein_coding | tolerated(0.18) | benign(0.013) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
VARS2 | SNV | Missense_Mutation | novel | c.3119N>C | p.Leu1040Pro | p.L1040P | Q5ST30 | protein_coding | deleterious(0.02) | probably_damaging(0.988) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
VARS2 | SNV | Missense_Mutation | novel | c.369N>T | p.Lys123Asn | p.K123N | Q5ST30 | protein_coding | deleterious(0) | benign(0.395) | TCGA-A5-A2K5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
VARS2 | SNV | Missense_Mutation | c.646G>A | p.Ala216Thr | p.A216T | Q5ST30 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-AJ-A2QO-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
VARS2 | SNV | Missense_Mutation | rs780294879 | c.1178G>A | p.Arg393Gln | p.R393Q | Q5ST30 | protein_coding | deleterious(0.01) | benign(0.294) | TCGA-AJ-A3EL-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
VARS2 | SNV | Missense_Mutation | novel | c.1413G>T | p.Lys471Asn | p.K471N | Q5ST30 | protein_coding | tolerated(0.1) | possibly_damaging(0.888) | TCGA-AJ-A3EL-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
VARS2 | SNV | Missense_Mutation | rs773112651 | c.1138N>A | p.Val380Ile | p.V380I | Q5ST30 | protein_coding | tolerated(0.07) | benign(0.194) | TCGA-AJ-A8CW-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
VARS2 | SNV | Missense_Mutation | novel | c.622N>A | p.Leu208Met | p.L208M | Q5ST30 | protein_coding | deleterious(0) | possibly_damaging(0.757) | TCGA-AP-A051-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
VARS2 | SNV | Missense_Mutation | novel | c.994C>A | p.Gln332Lys | p.Q332K | Q5ST30 | protein_coding | tolerated(0.26) | benign(0) | TCGA-AP-A0LD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |